Mind Medicine (MNMD) Tops Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
MindMed Reports First Quarter 2022 Financial Results and Business Highlights
May 16, 2022 7:30 AM EDT- Advanced clinical programs for three lead drug candidates -
- Strengthened leadership team with the appointment of Francois Lilienthal, MD as Chief Commercial Officer -
- Cash runway through key clinical readouts in 2023 and into 2024 -
- Company to host conference call today at 8:30 AM ET -
NEW YORK, May 16, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain... More
